- Home
- ANTX
as 07-26-2024 4:00pm EST
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 63.5M | IPO Year: | 2022 |
| Target Price: | $4.00 | AVG Volume (30 days): | 155.9K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.91 - $22.22 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of AN2 Therapeutics Inc. (ANTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zakrzewski Joseph S | ANTX | Director | Jan 18 '24 | Sell | $19.11 | 100,000 | $1,911,410.00 | 405,880 | SEC Form 4 |
| Adjuvant Global Health Technology Fund, L.P. | ANTX | 10% Owner | Jan 16 '24 | Sell | $19.65 | 84,093 | $1,652,427.45 | 1,995,958 | SEC Form 4 |
| Adjuvant Global Health Technology Fund, L.P. | ANTX | 10% Owner | Jan 16 '24 | Sell | $19.65 | 15,907 | $312,572.55 | 377,542 | SEC Form 4 |
| Aziz Kabeer | ANTX | Director | Jan 16 '24 | Sell | $19.65 | 84,093 | $1,652,427.45 | 1,995,958 | SEC Form 4 |
| Aziz Kabeer | ANTX | Director | Jan 16 '24 | Sell | $19.65 | 15,907 | $312,572.55 | 377,542 | SEC Form 4 |
| Readnour Robin Shane | ANTX | Director | Jan 12 '24 | Sell | $21.92 | 706 | $15,475.52 | 414,788 | SEC Form 4 |
| Readnour Robin Shane | ANTX | Director | Jan 12 '24 | Sell | $21.91 | 719 | $15,753.29 | 485,073 | SEC Form 4 |
| Readnour Robin Shane | ANTX | Director | Jan 10 '24 | Sell | $21.93 | 1,869 | $40,987.17 | 415,494 | SEC Form 4 |
| Readnour Robin Shane | ANTX | Director | Jan 10 '24 | Sell | $21.92 | 1,800 | $39,456.00 | 485,792 | SEC Form 4 |
| Krause Kevin Michael | ANTX | Chief Strategy Officer | Jan 9 '24 | Sell | $20.14 | 7,417 | $149,367.25 | 1,914 | SEC Form 4 |
| Krause Kevin Michael | ANTX | Chief Strategy Officer | Jan 2 '24 | Sell | $20.12 | 2,583 | $51,967.12 | 1,914 | SEC Form 4 |
| Easom Eric | ANTX | Chief Executive Officer | Jan 2 '24 | Sell | $20.09 | 2,777 | $55,802.43 | 2,130 | SEC Form 4 |
| Adjuvant Global Health Technology Fund, L.P. | ANTX | 10% Owner | Nov 14 '23 | Sell | $16.15 | 1,522 | $24,574.21 | 2,080,051 | SEC Form 4 |
| Adjuvant Global Health Technology Fund, L.P. | ANTX | 10% Owner | Nov 14 '23 | Sell | $16.15 | 288 | $4,650.05 | 393,449 | SEC Form 4 |
Latest AN2 Therapeutics Inc. News
ANTX Breaking Stock News: Dive into ANTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
The Fly
23 days ago
Intuit initiated, Charter downgraded: Wall Street's top analyst calls
Zacks
2 months ago
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
Business Wire
2 months ago
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
Business Wire
4 months ago
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
Insider Monkey
5 months ago
13 Best Falling Stocks To Buy Right Now
Reuters
5 months ago
UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment
Reuters
5 months ago
AN2 Therapeutics to pause lung disease study enrollment
Compare ANTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANTX AN2 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.